Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00094848 · ClinicalTrials.gov registry record · Phase 2

Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

A Phase 2 study, sponsored by Human Genome Sciences.

Completed
Registry status
Phase 2
Development phase

NCT00094848: Completed Phase 2 study, sponsored by Human Genome Sciences.

NCT00094848 is a Phase 2 study that has completed, run by Human Genome Sciences. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00094848, a Phase 2 study, has completed, sponsored by Human Genome Sciences.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

The purpose of this study is to evaluate the safety, efficacy and exposure to TRM-1 in subjects with relapsed or refractory Non-Hodgkin's Lymphoma (NHL).

Interventions

  • DRUG TRAIL-R1 mAb (TRM-1; HGS-ETR1)

Trial Details

FieldValue
Start Date 2004-06
Est. Completion 2007-05
Phase Phase 2
Human Genome Sciences

17 total trials

What the finished NCT00094848 record still lists

NCT00094848 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which TRAIL-R1 mAb (TRM-1; HGS-ETR1) is the first listed.

NCT00094848 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00094848 about?

NCT00094848 is a clinical study titled "Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)". The purpose of this study is to evaluate the safety, efficacy and exposure to TRM-1 in subjects with relapsed or refractory Non-Hodgkin's Lymphoma (NHL).

What is the current status of trial NCT00094848?

This trial is currently completed. It is a Phase 2 study. The study started on 2004-06. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00094848?

The interventions under investigation include: TRAIL-R1 mAb (TRM-1; HGS-ETR1) (DRUG).

Who is sponsoring clinical trial NCT00094848?

This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00094848, the US trial registry maintained by the National Library of Medicine. NCT00094848 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.